On March 31, 2025 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in in two upcoming investor conferences (Press release, Revolution Medicines, MAR 31, 2025, View Source [SID1234651685]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s participation are as follows:
Needham 24th Annual Virtual Healthcare Conference
Fireside Chat: Monday, April 7 at 2:15 p.m. ET
Stifel 2025 Virtual Targeted Oncology Forum
Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: View Source Following the live webcasts, replays will be available on the company’s website for at least 14 days.